ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics ...

Orion Corporation ("Orion"), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today ...

ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody ...

Theradaptive, a Maryland-based, privately held, clinical-stage biologics company, today announced the initiation of patient dosing in Maryland for the ongoing OASIS Phase I/II clinical trial assessing ...

Nurse Capital, a venture capital fund that invests in early-stage healthcare startups founded and led by nurses, is proud to announce the launch of the Nurse Capital Network (NCN), an exclusive, ...

2 Invenra has launched its Rapid Antibody Discovery Service, designed to simplify and de-risk the preclinical development of bispecific antibodies while reducing costs and enhancing downstream ...

The ADC is due to start testing in humans this year. Earlier deals included a collaboration with Invenra on ‘multispecific’ antibodies that can target more than one target simultaneously ...

One of the losers of today's trading session was Exelixis. Shares of the Biotechnology company plunged -6.3%, and some investors may be wondering if its price of $31.98 would make a good entry point.

Shares of Biotechnology company Exelixis jumped 4.4% today. With many investors piling into EXEL without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick ...

The Business Launcher simplifies the entrepreneurial journey by offering a personalized, end-to-end solution that translates users' skills and experiences into viable business ventures.